Eli Lilly’s Mounjaro (tirzepatide) delivered better blood sugar control and weight loss than other GLP-1 medications when added early in Type 2 diabetes treatment, according to a new study published May 26 in Annals of Internal Medicine. The Surpass-Early trial…
GLP-1s
CVS Caremark has expanded coverage options for GLP-1 weight management medications, including the return of Zepbound as a preferred formulary option — reversing a decision that drew significant patient pushback. CVS Caremark initially selected Wegovy as the preferred GLP-1 for…
Eli Lilly’s new obesity drug is posting weight loss results that rival — and in some cases exceed — gastric bypass surgery, long considered the only effective treatment for most patients with severe obesity. Lilly announced May 21 that its…
In 2026, the U.S. prescription drug market is predicted to exceed $1 trillion for the first time, and GLP-1 drugs such as Ozempic, Zepbound and Wegovy are the primary drivers of this growth. GLP-1s accounted for 14% of U.S. drug…
Maryland’s Prescription Drug Affordability Board has voted to place an upper payment limit on Ozempic for state and local government health plans, a first for the nation, and a move supporters said could save about $5.8 million annually. The board…
Advertisement
CMS launches its Medicare GLP-1 Bridge July 1, giving eligible Medicare Part D beneficiaries access to weight-loss GLP-1s at a $50 monthly copay through December 2027. For health systems and pharmacy leaders, the launch means new workflow requirements, a likely…
Novo Nordisk said oral Wegovy outperformed Eli Lilly’s orforglipron on weight loss and treatment tolerability in new analyses. The company shared findings from its Orion indirect treatment comparison and Optic patient preference studies, which compared 25-milligram oral semaglutide with 36-milligram…
Americans are unlikely to see generic versions of semaglutide — the active ingredient in Novo Nordisk’s Ozempic and Wegovy — until at least the end of 2031, according to a May 13 NBC News report. Novo Nordisk first applied for…
An analysis of more than 430,000 patients found metabolic and bariatric surgery results in 20 percentage-point greater weight loss than GLP-1 receptor agonist use, according to an article in the April issue of Surgery for Obesity and Related Diseases. Results…
Roughly half of the clients served by CVS Health’s pharmacy benefit manager cover GLP-1s, company leadership said May 6 on a quarterly earnings call. CVS Caremark, CVS’ PBM, serves employers and healthcare payers more broadly. Executive Vice President and Group…